Medically Supervised Weight Management Programme
Evidence-based, ABI-informed weight management — addressing the neurological, hormonal and pharmacological drivers of weight change in brain injury survivors.
Weight change following Acquired Brain Injury is extremely common and rarely straightforward. It is not a lifestyle issue — it is a clinical one. The causes are multifactorial and deeply embedded in the neurobiology of brain injury: neuroendocrine disruption reducing metabolic rate, significantly impaired mobility limiting energy expenditure, hypothalamic damage causing hyperphagia or abnormal appetite regulation, and the weight-promoting effects of commonly prescribed ABI medications.
Our medically supervised weight management programme addresses these root causes with a bespoke, clinically structured plan that integrates dietary guidance, physical activity support, pharmacological intervention where appropriate and clinically indicated, and ongoing monitoring and reporting to the care team.
Why ABI patients are at significantly elevated risk:
Neurological drivers
- Hypothalamic damage causing hyperphagia, impaired satiety signalling and abnormal appetite regulation
- Growth hormone deficiency increasing central adiposity and reducing lean muscle mass
- Disrupted cortisol and insulin regulation increasing metabolic risk
- Impaired executive function reducing capacity for self-directed dietary change
- Emotional dysregulation and impulsivity affecting eating behaviour
Physical and functional drivers
- Significantly reduced mobility and prolonged bed or wheelchair dependency
- Spasticity and pain limiting exercise tolerance
- Fatigue — both neurological and endocrine in origin — reducing activity capacity
- Dysphagia leading to high-calorie modified texture diets
- Reduced autonomy and dependence on carers for food preparation
Pharmacological drivers
- Antipsychotic medications (highly weight-promoting — metabolic monitoring mandatory)
- Anticonvulsants — particularly valproate, gabapentin, pregabalin
- Tricyclic antidepressants and mirtazapine
- Corticosteroids (short or long-term)
- Opioid analgesics reducing activity and increasing sedation
- Sedative medications reducing basal metabolic activity
A patient must meet ALL of the following criteria to be considered for pharmacological treatment:
Medical assessment — what is included at initial consultation:
Physical assessment
- BMI, waist circumference, body fat percentage (where measurable)
- Blood pressure, resting heart rate
- Fasting glucose, HbA1c — type 2 diabetes screening
- Full lipid profile — total cholesterol, HDL, LDL, triglycerides
- Thyroid function — TSH, free T4, free T3
- Cortisol, insulin resistance markers (fasting insulin, HOMA-IR)
- QRISK3 cardiovascular risk score calculated
- Liver function tests — NAFLD/NASH screening
- Full blood count and renal function
- Physical activity capacity assessment with carer input
Clinical and behavioural review
- Medication review — identification of all weight-promoting agents in current regimen
- Nutritional intake assessment — dietary history, feeding route, modified texture requirements
- Eating behaviour review — hyperphagia, impulsivity, food-seeking behaviour
- Previous weight management interventions — documented outcomes
- Psychological factors — depression, anxiety, boredom-eating
- Carer and support worker capacity to support dietary and activity plan
- Mental Capacity Act status — consent or Best Interests pathway
- Social factors — food availability, preparation support, budget
Programme components:
The programme is individualised and reviewed monthly. Components are adjusted based on clinical response, tolerability and any changes to the patient’s wider care plan.
Dietary and lifestyle intervention
- Personalised caloric target based on estimated basal metabolic rate and activity level
- Macronutrient targets — protein prioritised to preserve lean mass in the context of reduced activity
- ABI-adapted dietary guidance — accounts for cognitive, behavioural and swallowing factors
- Practical guidance for carers and support workers on food preparation and portion management
- Structured physical activity plan within the patient's mobility and fatigue limits
- Coordination with physiotherapy and occupational therapy teams where applicable
- Behavioural strategies for managing hyperphagia and impulsive eating in ABI context
Pharmacological intervention (where clinically indicated)
- Prescribing of pharmacological weight management agents where NICE NG238 eligibility criteria are met (see below)
- All medication decisions made by a registered clinician following full medical assessment
- Drug class options discussed with the patient (or Best Interests decision-maker) at consultation — specific medications not advertised
- Medication review and rationalisation — deprescribing or switching weight-promoting agents where clinically safe
- Titration schedule followed per NICE/MHRA approved prescribing information
- Monthly clinical review during titration phase
- 6-monthly metabolic review panel once on stable dose
- Progress reports issued to case manager and financial deputy at each review
Frequently Asked Questions
Our FAQ section is here to answer the most common questions about this service and help you feel fully informed before getting started. If you don’t see the answer you’re looking for, please don’t hesitate to get in touch—our team is always happy to help and provide clarity where needed.
Why is weight management considered a clinical service rather than a lifestyle programme for ABI patients?
Weight change following Acquired Brain Injury has clinical drivers that are fundamentally different from weight gain in the general population. Hypothalamic damage disrupts appetite regulation and satiety signalling; pituitary dysfunction reduces growth hormone and raises cortisol, promoting central adiposity; significantly reduced mobility limits energy expenditure; and many of the medications prescribed post-ABI — including antipsychotics, anticonvulsants and antidepressants — have substantial weight-promoting effects. Self-directed lifestyle change is rarely effective or even possible for patients with significant cognitive, physical or behavioural impairment. A medically supervised clinical approach is therefore not optional — it is the appropriate standard of care.
Which medications commonly prescribed after a brain injury cause weight gain?
The most significant weight-promoting medications in the ABI population are the atypical antipsychotics (olanzapine, quetiapine and clozapine being particularly problematic), sodium valproate and other anticonvulsants (especially gabapentin and pregabalin), mirtazapine and tricyclic antidepressants, corticosteroids used in the acute phase, and opioid analgesics which both increase appetite and reduce activity. Our medication review service (Service 09) works alongside the weight management programme to identify and rationalise weight-promoting agents where clinically safe to do so.
What does the initial weight management assessment involve?
The initial assessment is a comprehensive medical consultation covering: BMI, waist circumference and blood pressure; fasting glucose, HbA1c and full lipid profile; thyroid function and cortisol; QRISK3 cardiovascular risk calculation; full medication review for weight-promoting agents; nutritional and behavioural history including carer-reported eating patterns; physical activity capacity assessment; and Mental Capacity Act status. A personalised programme is then produced, including dietary targets, an activity plan, medication optimisation recommendations, and pharmacological treatment where NICE NG238 criteria are met.
What pharmacological weight management treatments are available at Nexus ABI?
Where a patient meets the clinical eligibility criteria set out in NICE guideline NG238, our clinician will discuss all available pharmacological treatment options at the consultation. We are unable to name specific prescription medications in our published materials under UK advertising regulations (MHRA/ASA rules on prescription-only medicine promotion), but our clinician will explain all relevant options — including drug class, mechanism, expected outcomes, titration schedule and side effect profile — clearly and transparently within the consultation. All prescribing decisions are made at the discretion of our registered clinician following a full medical assessment.
What are the NICE NG238 criteria for pharmacological weight management treatment?
To be considered for pharmacological weight management treatment under NICE NG238, a patient must have a BMI of 30 kg/m² or above (or 27.5 kg/m² or above for individuals of South Asian, Chinese, Black African or Black Caribbean background), plus at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidaemia or obstructive sleep apnoea. Non-pharmacological measures must have been documented, a full medical assessment completed, and either the patient’s informed consent or a Best Interests decision under the Mental Capacity Act must be in place. Ongoing clinical monitoring is also mandatory.
How does the programme account for patients who lack capacity to make decisions about their treatment?
Where a patient lacks capacity to consent to the weight management programme or pharmacological treatment, we follow the Mental Capacity Act 2005 Best Interests framework as standard. A Best Interests decision will be documented in consultation with the case manager, family or appointed deputy, and the patient’s wishes and preferences are explored and recorded. All Best Interests decisions and the rationale for treatment are documented in writing and available for deputyship and Court of Protection review.
Can the weight management programme be delivered entirely in the patient's home?
Yes. Our consultations can be conducted via our secure video platform or as in-person home visits as clinically indicated. Blood tests are carried out in-home by our phlebotomy team. Medication, where prescribed, is delivered to the patient’s address by our partner pharmacy. Monthly review consultations are conducted remotely by default, with in-person visits scheduled where a physical examination is required. The programme is designed to be delivered with minimal disruption to the patient’s routine and care arrangements.
How is progress monitored and reported to the case manager?
Progress is reviewed monthly during the active phase of the programme. Each review includes weight, blood pressure, symptom assessment and medication tolerance review. Blood tests are repeated at 3 months and 6 months. A structured progress report is produced at each formal review and shared securely with the referring case manager and financial deputy. Reports include weight trajectory, metabolic changes, medication status, and any clinical recommendations or concerns. We can align reporting with case management review cycles on request.
What results can be realistically expected from the programme?
Outcomes vary significantly depending on the patient’s baseline, the underlying drivers of their weight gain, their mobility and functional capacity, and whether pharmacological treatment is appropriate and tolerated. Where pharmacological treatment is initiated and tolerated, clinical trials have demonstrated average weight reductions of 10–22% of body weight over 12–18 months. Even modest weight reduction of 5–10% of body weight produces clinically meaningful improvements in blood pressure, blood glucose, lipid profile, joint loading and cardiovascular risk. Our clinical team sets realistic, individualised targets at the outset and reviews them at each milestone.
How is the programme funded?
The weight management programme is eligible for funding through personal injury settlement budgets, Court of Protection deputyship funds, and NHS Continuing Healthcare where the clinical criteria are met. We provide fully itemised clinical invoicing at each stage, with clear documentation of the clinical rationale for treatment — suitable for deputyship audit and Court of Protection review. Medication costs, where applicable, are billed separately at cost plus a dispensing administration fee, with full transparency.